NCT04868799

Brief Summary

The investigators aim to explore the inter tumor heterogeneity by a proteomic approach of a wide series of rhabdoid tumors, from both intra and extra cranial origins.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 29, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 3, 2021

Completed
1.3 years until next milestone

Study Start

First participant enrolled

August 12, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 17, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 17, 2023

Completed
Last Updated

November 20, 2025

Status Verified

October 1, 2025

Enrollment Period

6 months

First QC Date

April 29, 2021

Last Update Submit

November 17, 2025

Conditions

ATRT

Keywords

SMARCB1ATRTBrain TumorsProteomicMulti-omics

Outcome Measures

Primary Outcomes (1)

  • Identification of proteomic signature for each molecular subgroup of ATRT

    3 years

Study Arms (1)

ATRT

Patients \<18 years with an ATRT having frozen samples

Biological: Mass spectrometry

Interventions

Mass spectrometryBIOLOGICAL

Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry

ATRT

Eligibility Criteria

AgeUp to 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

cohort of clinically, radiologically and histopathologically annoted ATRT

You may qualify if:

  • Aged 0-17 years old
  • Rhabdoid tumor, treated in oncology departments in Ile de France
  • frozen samples collected in usual care
  • parents' agreement for samples collection in usual care

You may not qualify if:

  • Unconfirmed diagnosis of Rhabdoid tumor with molecular analyses Samples
  • paraffin embedded tissues

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service de neurochirurgie - Hôpital Necker Enfants malades

Paris, 75015, France

Location

MeSH Terms

Conditions

Brain Neoplasms

Interventions

Mass Spectrometry

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Chemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Kevin Beccaria, MD, PhD

    APHP Assistance Publique des Hôpitaux de Paris

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 29, 2021

First Posted

May 3, 2021

Study Start

August 12, 2022

Primary Completion

February 17, 2023

Study Completion

February 17, 2023

Last Updated

November 20, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)